Literature DB >> 12186930

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.

Christian T Ruff1, Stuart C Ray, Patricia Kwon, Rebekah Zinn, Amanda Pendleton, Nancy Hutton, Roxann Ashworth, Stephen Gange, Thomas C Quinn, Robert F Siliciano, Deborah Persaud.   

Abstract

Although highly active antiretroviral therapy (HAART) for human immunodeficiency virus type 1 (HIV-1) infection can reduce levels of HIV-1 RNA in plasma to below the limit of detection, replication-competent forms of the virus persist in all infected individuals. One form of persistence involves a stable reservoir of latent but potentially infectious virus that resides in resting memory CD4(+) T cells. The mechanisms involved in maintaining this latent reservoir are incompletely understood. In the present study, we examined the dynamic characteristics of this reservoir in a cohort of children who developed drug-resistant HIV-1 as a result of extensive exposure to inadequately suppressive one- or two-drug regimens prior to the advent of HAART. We have previously shown that drug-resistant viruses selected by nonsuppressive pre-HAART regimens can enter and persist in this reservoir. We have extended these findings here by demonstrating that archival wild-type HIV-1 persists in this reservoir despite the fact that in these patients drug-resistant mutants have been favored by the selective conditions for many years. Phylogenetic analysis of replication-competent viruses persisting in resting CD4(+) T cells revealed a striking lack of temporal structure in the sense that isolates obtained at later time points did not show greater sequence divergence than isolates from earlier time points. The persistence of drug-sensitive virus and the lack of temporal structure in the latent reservoir provide genetic evidence for the idea that HIV-1 can persist in a latent form free of selective pressure from antiretroviral drugs in long-lived resting memory CD4(+) T cells. Although there may be other mechanisms for viral persistence, this stable pool of latently infected cells is of significant concern because of its potential to serve as a lasting source of replication-competent viruses, including the infecting wild-type form and all drug-resistant variants that have arisen subsequently.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186930      PMCID: PMC136462          DOI: 10.1128/jvi.76.18.9481-9492.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.

Authors:  D Persaud; T Pierson; C Ruff; D Finzi; K R Chadwick; J B Margolick; A Ruff; N Hutton; S Ray; R F Siliciano
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Emergence of zidovudine resistance in HIV-infected patients receiving stavudine.

Authors:  C de Mendoza; V Soriano; C Briones; O Gallego; P Barreiro; A Alvarez; J González-Lahoz
Journal:  J Acquir Immune Defic Syndr       Date:  2000-03-01       Impact factor: 3.731

3.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

4.  Persistence of memory CD8 T cells in MHC class I-deficient mice.

Authors:  K Murali-Krishna; L L Lau; S Sambhara; F Lemonnier; J Altman; R Ahmed
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

5.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Authors:  A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

7.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

8.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy.

Authors:  G Dornadula; H Zhang; B VanUitert; J Stern; L Livornese; M J Ingerman; J Witek; R J Kedanis; J Natkin; J DeSimone; R J Pomerantz
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

9.  Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

Authors:  L Zhang; C Chung; B S Hu; T He; Y Guo; A J Kim; E Skulsky; X Jin; A Hurley; B Ramratnam; M Markowitz; D D Ho
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

10.  Antiretroviral resistance during successful therapy of HIV type 1 infection.

Authors:  J Martinez-Picado; M P DePasquale; N Kartsonis; G J Hanna; J Wong; D Finzi; E Rosenberg; H F Gunthard; L Sutton; A Savara; C J Petropoulos; N Hellmann; B D Walker; D D Richman; R Siliciano; R T D'Aquila
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

View more
  55 in total

Review 1.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

2.  Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments.

Authors:  David C Nickle; Mark A Jensen; Daniel Shriner; Scott J Brodie; Lisa M Frenkel; John E Mittler; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 3.  HIV latency.

Authors:  Robert F Siliciano; Warner C Greene
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

5.  Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Authors:  Zabrina L Brumme; Hanwei Sudderuddin; Carrie Ziemniak; Katherine Luzuriaga; Bradley R Jones; Jeffrey B Joy; Coleen K Cunningham; Thomas Greenough; Deborah Persaud
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

Review 6.  Clinical and evolutionary consequences of HIV adaptation to HLA: implications for vaccine and cure.

Authors:  Santiago Avila-Rios; Jonathan M Carlson; Mina John; Simon Mallal; Zabrina L Brumme
Journal:  Curr Opin HIV AIDS       Date:  2019-05       Impact factor: 4.283

7.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.

Authors:  Moira A McMahon; Janet D Siliciano; Jun Lai; Jun O Liu; James T Stivers; Robert F Siliciano; Rahul M Kohli
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

9.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.